Grifols Worldwide

PharPoint Research Inc is a contract research organization (CRO) based in Durham, NC. With over 1,000 studies supported since 2007, PharPoint offers a client-centric approach to help innovative clients meet their clinical trial goals. Their services include clinical operations, project management, site feasibility study start-up, medical monitoring, clinical data management, biostatistics, medical writing, and more. PharPoint is known for their industry-best biometrics timelines, delivering study results over a month faster than the industry average, and their transparent, attentive, and accessible team. PharPoint's success stories and proven track record demonstrate their commitment to reducing challenges early in the trial process through strategic site selection, prioritizing data quality and cleaning, and providing custom programming without added costs. Their experienced team, extensive industry experience, and partnerships with EDC providers allow them to deliver quality results efficiently. Trusted by 180 companies, PharPoint is dedicated to supporting clients from pre-IND planning through regulatory approval, ultimately contributing to the improvement of global health.Generated from the website

Impact Pharmaceutical Service, LLC is a company based in Research Triangle Park, NC, specializing in providing comprehensive pharmaceutical services to clients in the healthcare industry. With a focus on quality and efficiency, Impact Pharmaceutical Service, LLC offers a range of solutions to support drug development, regulatory submissions, and compliance requirements. Generated from their business information

Aeolus Pharmaceuticals Inc. is a biopharmaceutical company based in Durham, NC, focused on developing a platform of compounds for use in biodefense, oncology, and diseases affecting the central nervous system. The company's lead compound, AEOL 10150, has shown promise in protecting healthy tissue from radiation damage while enhancing tumor control when used in combination with radiation and chemotherapy. With over $150 million in government funding supporting its development programs, Aeolus aims to leverage this investment to address large market opportunities in both oncology and biodefense. The company has secured a contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop a medical countermeasure for pulmonary acute radiation syndrome, positioning it to potentially make significant contributions to public health and cancer treatment. Generated from the website